Hematology

Friday, April 25, 2014


08:30-10:00
IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): SOME ASPECTS OF TREATMENT
Capsule During the past three decades intravenous gammaglobulin therapy has evoked clinical and laboratory research on the mechanisms of action in disorders with immune   pathogenesis. It was recognized that IVIG modulates the disturbed immune response in multiple, synergistic ways between the different components of the immune system. Following this observation anti-D immunonoglobulin, anti-CD monoclonal antibodies and cyclosporin A – probably also the thrombopoietin receptor antagonists – were recognized as biologic immunomodulators. The various mechanisms of action of immunomodulators will be discussed
Chairperson P. Imbach, Switzerland
08:30 Immunomodulation in ITP
P. Imbach, Switzerland
09:00
Debate:  Intervention in childhood ITP: Yes or no?
Yes: A. Schifferli, Switzerland .
No:   P. Bolton-Maggs, UK  
Discussion

10:20-11:50
IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): TREATMENT MODALITIES
Chairpersons P. Imbach, Switzerland
T. Kuehne
, Switzerland
10:20 Update on the intercontinental cooperative ITP study group (ICIS) and on the pediatric registry on chronic ITP (PARC ITP)
T. Kuehne, Switzerland
10:50 Duration and morbidity of chronic immune thrombocytopenic purpura in children: Results of the Nordic cohort
S. Rosthoej, Denmark
11:20 Children with acute ITP should be treated only according to bleeding score
S. Revel-Vilk, Israel

12:10-13:40
APLA, ANTI PHOSPHOLIPID SYNDROME (APS): UNIQUE PRESENTATION OR A DIFFERENT ENTITY
Capsule
APLA and APS in children: Adult criteria for diagnosis of antiphospholipid syndrome (APS) are applied for pediatric cases as well, although recurrent pregnancy loss is not applicable for children. As perinatal arterial stroke may present with persistent antiphospholipid antibodies (and thus be defined as APS), either unique APS presentation or a different entity in infants should be considered, and certainly affects future management.
Chairpersons: N. Toplak, Slovenia
V. Pengo, Italy 
12:10 Diagnostic criteria for APS
V. Pengo, Italy 
12:40 Pediatric APS and the international pediatric-APS registry
N. Toplak, Slovenia
13:10 Lab diagnosis of APLA
G. Sarig, Israel

14:30-16:00
HEMOSTASIS AND ADOLESCENTS
Capsule Estrogen therapy increases the risk of thrombosis. The increased risk is related to type and dose of both estrogen and combined progestagen and mode of delivery. Many questions arise, like: Which kind of oral contraceptive should we prescribe? Is thrombophilia testing in adolescents females required? And more
Chairpersons: B. Brenner, Israel
J. Rabinovici
, Israel
14:30 Oral contraceptives: Which kind should we prescribe?
J. Rabinovici, Israel 
15:00 Is thrombophilia testing in adolescents useful?
B. Brenner, Israel
15:30 Menorrhagia in adolescents
S. Revel-Vilk, Israel

 

Saturday, April 26, 2014


08:30-10:00
INHERITED BONE MARROW FAILURE
Capsule
Inherited Bone Marrow Failure (IBMF) – including Fanconi anemia, Diamond Blackfan Anemia, severe congenital neutropenia, Shwachman-Diamond syndrome, dyskeratosis congenital, congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii - is a relatively rare entity in pediatrics, however, early and prompt diagnosis are crucial for optimal therapy and genetic counseling. Bicytopenia and pancytopenia may be encountered quite often in the first years of life. In this session we will highlight the specific characteristics of IBMF (physical examination, laboratory work-up and more) that will direct us to the diagnosis of IBMF.
Chairperson H. Tamary, Israel
08:30 Overview: Inherited Bone Marrow Failure
H. Tamary, Israel
09:00 Approach to Neutropeia in children
K. Welte, Germany
09:30 The neonatologist and the diagnosis of inherited bone marrow failure syndromes
C. Dufour, Italy

10:20-11:50
ANEMIA
Capsule Anemia of acute infection – frequently seen, however a big enigma – will be characterized in the session. Clinical studies disclose frequency and severity of this phenomenon. An animal model (mouse) proposes the pathophysiology
Chairperson A. Ballin, Israel
10:20 Iron deficiency anemia: Still a problem
A. Ballin
. Israel
10:50 Autoimmune Hemolytic Anemia
H. Tamary, Israel
11:20 Anemia of acute infection
A. Ballin, Israel

12:10-13:40
NEONATAL INTRAVENTRICULAR HEMORRHAGE (IVH): IS THIS A BLEEDING DISORDER?
Capsule
Neonatal IVH is a devastating complication of prematurity. The immature fetal hemostatic systems render those infants, born extremely premature, highly susceptible for bleeding. Nonetheless, as coagulation inhibition is seriously impaired, the risk of thrombosis following venous congestion is also increased
Chairpersons G. Kenet, Israel
L. Ramenghi, Italy
12:10
Debate:  
Is IVH of prematurity a bleeding disorder? G. Kenet, Israel
Is IVH a result of thrombophilic risk factors? L. Ramenghi, Italy
Panelists:
G. Kenet, Israel
L. Ramenghi, Italy

 

Panel discussion on the following topics:

  1. How often should we screen for IVH in the first day/days of life?
  2. Should premature infants be screened for coagulopathy?
  3. Once IVH grade 1-2 is diagnosed should we treat? Should we wait? How to treat?

14:30-16:00
PEDIATRIC VENOUS THROMBOEMBOLISM (VTE)
Chairperson U. Nowak-Göttl, Germany
14:30 Epidemiology of VTE in children
U. Nowak-Göttl, Germany
15:00
Debate: Should we screen kids with Central Vein Line thrombosis for thrombophilia?
Yes: A.C. Molinari, Italy
No: H. Van Ommen, Netherlands
Discussion

16:30-18:00
NEONATAL THROMBOSIS AND CONGENITAL BLEEDING DISORDERS
Capsule
Neonatal thrombosis is far more prevalent as compared to late childhood, yet chances of recurrent thrombosis in infants are slim. In the following session some common aspects of diagnosis and treatment of typical thromboembolic events in infants will be discussed. The lecturers will address pathophysiology, diagnosis and therapy of renal vein thrombosis, portal vein thrombosis and cerebral sinus vein thrombosis in neonates
Chairpersons M. Van Den Berg, Netherlands
A.K. Chan, Canada
16:30 Hemostasis in neonates: Developmental aspects
G. Kenet, Israel
17:00 Abdominal thrombosis of neonates (RVT, PVT)
A.K. Chan, Canada 
17:30

Inhibitor epidemiology and risk factors-lessons learned from international hemophilia multicenter studies
M. Van Den Berg, Netherlands


Sunday, April 27, 2014


08:30-10:00
CONTROVERSIES IN CHILDREN WITH IMPAIRED BETA-CELL FUNCTION: TOO MUCH OR TOO LITTLE INSULIN
Chairperson K. Hussain, UK
08:30 Neonatal diabetes: To treat with insulin or sulphonylureas?
J. Lebl, Czech Republic
09:00 Controversies in children with hyperinsulinism
K. Hussain, UK  
09:30
Genetic investigation in children with diabetes. Who investigates and who doesn’t?
S. Pruhova, Czech Republic

10:30-11:30
PEDIATRIC STROKE
Capsule

Stroke in children is a rare but significant cause of death and long-term disability. With increased understanding, improved guidelines, and emerging treatment options for children's stroke, increased awareness about this disease is necessary for prompt identification and treatment in this population

Chairperson U. Nowak-Göttl, Germany
10:30 Old and new risk factors for pediatric stroke
U. Nowak-Göttl, Germany 
11:00 Genome wide association studies in pediatric stroke
M. Stoll, Germany 

 
book_167

Scientific

Registration & Accommodation

Sponsorship & Exhibition